Davidson Michael H.

Director

Tenax Therapeutics, Inc.

US, Morrisville [HQ]

CIK 1573785

Data Source

We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.

Latest Information

606,645

Price per Share :

$6.48

Equivalence :

$3,931,059.60

Transaction History

A

Form 4

606,645 Shares After Transaction

Value : $n/a

$0.0

Transaction Date : 06/11/21
- Footnotes
- Form 4
Footnotes:
#1 On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021.

#2 As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction.
P

Form 4

2,881 Shares After Transaction

Value : $n/a

$0.0

Transaction Date : 08/08/24
- Footnotes
- Form 4
Footnotes:
#1 . On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock ("Shares") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99.

#2 The aggregate number of shares of common stock previously reported as 608,645, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.